Shares of vTv Therapeutics Inc (NASDAQ:VTVT) traded down 1.4% during trading on Monday . The company traded as low as $1.30 and last traded at $1.38. 1,288 shares were traded during trading, a decline of 100% from the average session volume of 1,471,709 shares. The stock had previously closed at $1.40.
A number of analysts recently commented on the stock. HC Wainwright assumed coverage on shares of vTv Therapeutics in a research note on Thursday, May 30th. They set a “buy” rating and a $5.00 price target on the stock. Northland Securities set a $3.00 price target on shares of vTv Therapeutics and gave the company a “hold” rating in a research note on Monday, March 18th. ValuEngine upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, May 23rd. Finally, Zacks Investment Research cut shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd.
The company has a market cap of $65.42 million, a P/E ratio of -2.13 and a beta of -3.69.
In other vTv Therapeutics news, major shareholder Ronald O. Perelman purchased 1,358,698 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $1.84 per share, for a total transaction of $2,500,004.32. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.70% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Barclays PLC grew its position in shares of vTv Therapeutics by 366.7% during the 4th quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 22,000 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new position in shares of vTv Therapeutics during the 4th quarter valued at $186,000. Wedbush Securities Inc. purchased a new position in shares of vTv Therapeutics during the 1st quarter valued at $30,000. Sabby Management LLC purchased a new position in shares of vTv Therapeutics during the 1st quarter valued at $382,000. Finally, Morgan Stanley grew its position in shares of vTv Therapeutics by 147,061.5% during the 1st quarter. Morgan Stanley now owns 19,131 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 19,118 shares in the last quarter. 3.94% of the stock is owned by hedge funds and other institutional investors.
vTv Therapeutics Company Profile (NASDAQ:VTVT)
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Featured Article: Percentage Decliners
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.